Serplulimab is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Serplulimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Serplulimab overview
Serplulimab (Hansizhuang, Zerpidio) is a recombinant humanized monoclonal antibody. It is formulated as solution , concentrate solution for intravenous route of administration. It is indicated for the treatment of adult patients with advanced unresectable or metastatic MSI-H (Microsatellite Instability-High) solid tumors that have failed to respond to previous standard treatments, providing an alternative treatment option for patients and squamous non-small cell lung cancer. It is also indicated in combination with carboplatin and albumin-bound paclitaxel for the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC)
Serplulimab (HLX-10) is under development for the treatment of solid tumors including hepatocellular carcinoma, metastatic colorectal cancer, metastatic esophageal squamous cell carcinoma, extensive stage small cell lung cancer, limited stage small cell lung cancer, nasopharyngeal cancer, squamous non-small cell lung cancer, metastatic non-squamous non-small cell lung cancer, microsatellite instability high or mismatch repair deficient solid tumors, lymphoma, gastric cancers mainly adenocarcinoma, metastatic large cell neuroendocrine lung carcinoma(LCNEC). The drug candidate is a humanized monoclonal antibody which acts by targeting PD-1. It is administered through intravenous route.
Serplulimab (HLX-10) was under development for the treatment of homologous-recombination deficient (HRD) triple-negative breast cancer (TNBC), chronic hepatitis B and lymphomas, cervical cancer.
Shanghai Henlius Biotech overview
Shanghai Henlius Biotech (Henlius), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a biopharmaceutical company that develops medicine for oncology, autoimmune and ophthalmic diseases. It offers HANLIKANG, a rituximab injection, which treats non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HERCESSI, trastuzumab for injection for breast, metastatic breast and metastatic gastric cancer; Handayuan, Adalimumab injection, which targets rheumatoid arthritis, Ankylosing spondylitis, Psoriasis, Uveitis, Crohn’s disease and Children Crohn’s disease; Hanbetac, Bevacizumab injection, which treats metastatic Colorectal, recurrent glioblastoma, epithelial ovarian cancer and others and Hans-Shape, Slulizumab injection, for microsatellite high instability (MSI-H) solid tumors, squamous non-small cell lung cancer (sqNSCLC). Henlius is headquartered in Shanghai, China.
For a complete picture of Serplulimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
